Novartis Hopes To Breathe New Life Into CAR-T Business With ASCO Myeloma Data

 
• By Alaric DeArment

Gilead’s Kite has taken a lead in multiple myeloma cell therapy while Novartis’s first-to-market Kymriah has slumped in sales, but the Swiss drug maker’s new data may support its effort to win on manufacturing time.

Novartis and Gilead's Kite Pharma at ASCO • Source: Alaric DeArment

More from ASCO

More from Conferences